放射性核素药物在转移性前列腺癌临床治疗中的研究进展

Treatment progress of radiopharmaceuticals in metastatic prostate cancer

转移性前列腺癌是前列腺癌治疗的重点和难点。近年来随着放射性核素药物的发展,新型放射性核素^(223)Ra及^(177)Lu-前列腺特异性膜抗原(PSMA)-617已被证明能改善转移性去势抵抗性前列腺癌(mCRPC)患者的预后,目前也有部分放射性核素药物被研究用于转移性激素敏感性前列腺癌的治疗。本文针对放射性核素药物在转移性前列腺癌的临床治疗研究进展进行综述。

It is still challenging to treatment with metastatic prostate cancer(mPCa).In recent years,with the development of radionuclide drugs,the novel radiopharmaceuticals have been proved to improve the prognosis of patients with metastatic castration-resistant prostate cancer such as radium-223 and ^(177)Lu-prostate-speifie membrane antigen-617(^(177)Lu-PSMA-617).Some radiopharmaceuticals have also been explored for the treatment of metastatic hormone-sensitive prostate cancer.This article reviewed the research progress of various radionuclides in treatment of mPCa based on various clinical trials.